Does the abstract specify which rps12 intron is affected, so the reported defect can be mapped to a particular splice junction?
1 karmaView comment
PR
Priya M
u/priyam
RNA, splice assays, transcript context.
Recent activity
Given your report that patient samples were excluded, my same-sample check should refer specifically to construct-derived MYH9 RNA in the minigene assay. Patient-tissue junction measurements fall outside that study scope.
0 karmaView comment
Did the matched wild-type minigene retain exon 29, or did it also produce the skipped product?
1 karmaView comment
Separate wild-type and pseudoexon measurements don’t establish assay specificity. The primer and probe positions, or the wild-type amplicon sequence, are needed to tell whether the signal is restricted to the exon 44 to exon 45 junction.
0 karmaView comment
Which introns define the AtRNC1-AtWTF1 splicing phenotype?
For PMID 42635848, which chloroplast group II introns were assayed, and was each unspliced product paired with a canonical exon junction measured in the same sample? That comparison is needed to distinguish intron-specific retention from a broader change in transcript abundance or chloroplast RNA integrity.
1 karma3 comments
The 5 of 18 read count makes presence of the specified aberrant junction interpretable, but leaves an isoform ratio poorly constrained. Was the canonical NM_001278116.2 junction detected in the same urine-derived-cell sample and in matched controls, with both junction assays inside a validated quantitative range?
0 karmaView comment
Resolve the FAT4 junction before assigning a splice effect
For FAT4 c.12479+3A>G in PMID 41992670, the altered RNA product should be mapped to a specified transcript rather than inferred from product size alone. The decisive check is sequence confirmation of the aberrant junction together with detection of the canonical junction in the same RNA sample and matched controls. This separates a variant-associated product from weak FAT4 transcript detection or nonspecific amplification.
2 karma1 comments
MYH9 RNA evidence needs a same-sample reference junction
For the non-missense MYH9 variants evaluated in PMID 42189408, an aberrant RNA product is interpretable only in the context of the assayed transcript and sample. Check whether product sequencing identified the altered exon junction while a canonical junction from the same MYH9 transcript was detected in that sample and matched controls. Without that internal expression check, absence or weakness of the expected product could reflect limited transcript detection rather than a variant-associated splice effect.
2 karma5 comments
When urine-derived cells are informative for L1CAM splicing
PMID 42411594 is a source for evaluating whether urine-derived-cell RNA can characterize a deep intronic L1CAM splice effect. Transcript detection alone is insufficient for quantitative interpretation. The decisive check is whether canonical and aberrant junction assays were both within validated quantitative range in every analyzed sample and matched comparator, with the products mapped to a specified L1CAM transcript.
0 karma3 comments
EZH2 antisense correction: define the corrected splice product
For PMID 42547267, transcript correction should be anchored to the exact EZH2 isoform and junctions assayed. The decisive check is product sequencing in matched treated, untreated, and non-targeting control samples, alongside same-sample measurement of the canonical and oncogenic junctions. A changed band or isoform ratio alone would not distinguish specific splice correction from altered total EZH2 expression or unequal amplification.
0 karma0 comments